Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Berk

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Immunotherapy|December 27, 2011
T-cell tolerance induced by non-Treg T-cell-derived TGF-β1Erik Berk, Ravikumar Muthuswamy
Immunotherapy|November 19, 2011
MKP-1 signaling translates innate signals into adaptive responsesErik Berk, Ravikumar Muthuswamy
Oncoimmunology|December 18, 2012
Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLsErik Berk, Pawel Kalinski
Immunotherapy|December 27, 2011
Treg-mediated angiogenesis and tolerance is programmed by hypoxia in the tumor microenvironmentErik Berk, Ravikumar Muthuswamy
Vaccine|May 8, 2012
Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLsErik Berk, Ravikumar Muthuswamy, Pawel Kalinski
Oncoimmunology|August 8, 2014
Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cellsErik Berk, Shuwen Xu, Brian J Czerniecki
Vaccines|September 8, 2015
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer TherapyJulia Terhune, Erik Berk, Brian J Czerniecki
Cancer Research|June 14, 2013
IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironmentJeffrey L Wong, Erik Berk, Robert P Edwards, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 29, 2011
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1Tridib Bhowmick, Erik Berk, Xiumin Cui, et al.
Future Oncology (London, England)|April 21, 2009
Dendritic cell-based therapeutic cancer vaccines: what we have and what we needPawel Kalinski, Julie Urban, Rahul Narang, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Immunotherapy|December 27, 2011
T-cell tolerance induced by non-Treg T-cell-derived TGF-β1Erik Berk, Ravikumar Muthuswamy
Immunotherapy|November 19, 2011
MKP-1 signaling translates innate signals into adaptive responsesErik Berk, Ravikumar Muthuswamy
Oncoimmunology|December 18, 2012
Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLsErik Berk, Pawel Kalinski
Immunotherapy|December 27, 2011
Treg-mediated angiogenesis and tolerance is programmed by hypoxia in the tumor microenvironmentErik Berk, Ravikumar Muthuswamy
Vaccine|May 8, 2012
Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLsErik Berk, Ravikumar Muthuswamy, Pawel Kalinski
Oncoimmunology|August 8, 2014
Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cellsErik Berk, Shuwen Xu, Brian J Czerniecki
Vaccines|September 8, 2015
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer TherapyJulia Terhune, Erik Berk, Brian J Czerniecki
Cancer Research|June 14, 2013
IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironmentJeffrey L Wong, Erik Berk, Robert P Edwards, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 29, 2011
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1Tridib Bhowmick, Erik Berk, Xiumin Cui, et al.
Future Oncology (London, England)|April 21, 2009
Dendritic cell-based therapeutic cancer vaccines: what we have and what we needPawel Kalinski, Julie Urban, Rahul Narang, et al.
Pageof 2